iTeos Therapeutics/$ITOS
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Ticker
$ITOS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
173
ISIN
US46565G1040
Website
ITOS Metrics
BasicAdvanced
$383M
-
-$3.09
1.43
-
Price and volume
Market cap
$383M
Beta
1.43
52-week high
$18.13
52-week low
$4.80
Average daily volume
2.1M
Financial strength
Current ratio
14.133
Quick ratio
13.78
Long term debt to equity
0.646
Total debt to equity
0.897
Profitability
EBITDA (TTM)
-148.649
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-373.75%
Operating margin (TTM)
-428.31%
Effective tax rate (TTM)
-10.99%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-14.54%
Return on equity (TTM)
-23.68%
Valuation
Price to revenue (TTM)
12.093
Price to book
0.68
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-4.218
Free cash flow yield (TTM)
-23.71%
Free cash flow per share (TTM)
-237.06%
Growth
Earnings per share change (TTM)
-18.24%
3-year revenue growth (CAGR)
-58.71%
3-year earnings per share growth (CAGR)
-26.31%
What the Analysts think about ITOS
Analyst ratings (Buy, Hold, Sell) for iTeos Therapeutics stock.
Bulls say / Bears say
Piper Sandler maintains an 'Overweight' rating on iTeos Therapeutics with a price target of $36.00, citing positive data from the European Society for Medical Oncology meeting where belrestotug combined with dostarlimab showed significant efficacy in treating PD-L1 high non-small cell lung cancer. (Investing.com)
Biotechnology Value Fund L.P. increased its stake in iTeos Therapeutics by adding 1,065,524 shares, indicating strong institutional confidence in the company's growth potential. (GuruFocus)
Analysts maintain a 'buy' rating on iTeos Therapeutics, with a median 12-month price target of $21.39, suggesting potential upside from the current trading price. (TradingView News)
iTeos Therapeutics and GSK discontinued the development of their experimental lung cancer therapy, belrestotug, after it failed to significantly improve progression-free survival in mid-stage trials. (Reuters)
Wells Fargo & Company lowered its price target for iTeos Therapeutics from $19.00 to $17.00, reflecting reduced expectations for the stock's performance. (MarketBeat)
Prudential Financial Inc. reduced its holdings in iTeos Therapeutics by 8.4%, indicating a decrease in institutional investor confidence. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
ITOS Financial Performance
Revenues and expenses
ITOS Earnings Performance
Company profitability
ITOS News
AllArticlesVideos
iTeos Therapeutics Announces Its Intention to Wind Down Operations
GlobeNewsWire·3 weeks ago
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewsWire·1 month ago
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iTeos Therapeutics stock?
iTeos Therapeutics (ITOS) has a market cap of $383M as of June 20, 2025.
What is the P/E ratio for iTeos Therapeutics stock?
The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of June 20, 2025.
Does iTeos Therapeutics stock pay dividends?
No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next iTeos Therapeutics dividend payment date?
iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.
What is the beta indicator for iTeos Therapeutics?
iTeos Therapeutics (ITOS) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.